LNC Therapeutics
Gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
€4.9m | Series C | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2018 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
YSOPIA Bioscience, formerly known as LNC Therapeutics, is a pioneering biotech company focused on developing next-generation microbiome-based therapies. The company harnesses the therapeutic potential of keystone single strain bacteria, particularly Christensenella, to address the fundamental causes of various illnesses. Operating in the biotech and pharmaceutical markets, YSOPIA Bioscience serves healthcare providers, patients, and research institutions seeking innovative treatments for metabolic and chronic diseases.
The business model revolves around extensive research and development (R&D) activities, clinical trials, and collaborations with academic institutions and pharmaceutical companies. YSOPIA Bioscience generates revenue through licensing agreements, partnerships, and potential future sales of its proprietary therapeutic solutions.
The company is led by a team of experienced professionals, including CEO Georges Rawadi and CSO Sandrine Claus, who bring a wealth of expertise in biotechnology, intellectual property, and integrative metabolism. YSOPIA Bioscience is committed to advancing its groundbreaking therapies to the clinic, aiming to become a major player in the field of microbiome-based biotherapies.
Keywords: microbiome, biotherapies, Christensenella, keystone bacteria, metabolic diseases, chronic illnesses, R&D, clinical trials, licensing, partnerships.